Effects of Hirudotherapy, Phytotherapy, and Forest Therapy in Adults With Reduced Work Capacity or Special Needs (CAM-HPMT)
Evaluation of the Biological Effects of Complementary and Alternative Health Care Services, Including Forest Therapy, Phytotherapy, and Hirudotherapy, in Individuals With Reduced Work Capacity and/or Special Needs
調査の概要
状態
詳細な説明
This randomized controlled interventional study will evaluate the biological, functional, and psychosocial effects of complementary and alternative health care services in individuals with a participation level below 55% and/or special needs. The study is designed to generate evidence for the development of standardized, accessible, and evidence-informed protocols for forest therapy, phytotherapy, and hirudotherapy.
A total of 100 participants will be enrolled and allocated to four groups of approximately 25 participants each: a phytotherapy group, a forest therapy group, a hirudotherapy group, and a control group receiving no study-related complementary and alternative health care intervention. Participants in the phytotherapy group will receive three phytotherapy sessions, participants in the forest therapy group will receive ten forest therapy sessions, and participants in the hirudotherapy group will receive six hirudotherapy sessions. The interventions will be delivered by appropriately qualified and licensed practitioners in accordance with Lithuanian legal and professional requirements.
Assessments will be conducted before and after the intervention period. Physiological and functional assessments will include blood pressure, body composition, and handgrip strength. Psychosocial outcomes will include psychological well-being, perceived stress, and sleep quality, assessed using standardized questionnaires, including the WHO-5 Well-Being Index, the 10-item Perceived Stress Scale, and the Pittsburgh Sleep Quality Index. Pre-intervention and post-intervention outcomes will be compared within and between the intervention and control groups.
The study will also evaluate the feasibility, accessibility, safety, and acceptability of providing these services to individuals with reduced participation and/or special needs. Reasonable accommodations may include accessible locations, adapted information formats, assistance with transportation or mobility, and support from accompanying persons when required.
Participant safety will be monitored throughout the study. Eligibility, contraindications, and potential risks will be assessed before the interventions. Any adverse events or unexpected reactions will be documented and evaluated. Particular attention will be given to contraindications and safety requirements associated with phytotherapy and hirudotherapy.
The results will be used to prepare standardized methodological materials and practical recommendations for complementary and alternative health care practitioners, health promotion programs, and social inclusion services.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Klaipėda County
-
Klaipėda、Klaipėda County、リトアニア、LT-92294
- Klaipeda University, Faculty of Health Sciences
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Individuals with a participation level below 55% and/or officially recognized special needs.
Ability and willingness to participate in the study procedures and assigned intervention.
Provision of written informed consent by the participant or, where applicable, by a legally authorized representative.
Ability to complete the planned assessments independently or with reasonable assistance.
Medical condition sufficiently stable to participate in the assigned complementary and alternative health care intervention.
Willingness to attend baseline and post-intervention assessments and the scheduled intervention sessions.
Exclusion Criteria:
Acute illness, fever, active infection, or clinically unstable health condition at the time of enrollment.
Any medical condition that, in the investigator's or intervention provider's judgment, would make participation unsafe.
Known contraindication to the intervention to which the participant may be assigned.
Current participation in another interventional study that could affect the study outcomes.
Inability to provide informed consent and absence of a legally authorized representative.
Inability to comply with the study procedures or intervention schedule despite reasonable accommodations.
Planned major medical procedure or substantial change in treatment during the study period that could influence the study outcomes.
Additional intervention-specific exclusion criteria:
Phytotherapy: known allergy or hypersensitivity to the planned herbal products; clinically relevant interactions with current medications; pregnancy or breastfeeding, when relevant to the selected herbal product; severe hepatic or renal impairment where the planned preparation may be contraindicated.
Hirudotherapy: bleeding disorders; clinically significant anemia; current anticoagulant or antiplatelet therapy when considered unsafe by the treating clinician; immunodeficiency; active skin infection or lesion at the planned application site; known allergy to leech-related substances; other contraindications identified by the licensed hirudotherapy practitioner.
Forest therapy: acute condition limiting safe participation outdoors; uncontrolled cardiovascular or respiratory symptoms; severe mobility, cognitive, behavioral, or sensory limitations that cannot be safely accommodated; severe allergy or environmental sensitivity relevant to the planned setting.
-
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：ヘルスサービス研究
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Phytotherapy Group
Participants assigned to this arm will receive three phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner.
The services will use legally permitted and appropriately sourced herbal products in accordance with Lithuanian professional and safety requirements.
Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
|
Participants assigned to the phytotherapy arm will receive three individualized phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner.
The intervention may include assessment, selection, and use of legally permitted herbal preparations or herbal products appropriate to the participant's health status and special needs.
Products will not be presented as investigational medicinal products.
Contraindications, possible interactions, tolerability, and adverse reactions will be assessed and monitored throughout the intervention period.
|
|
実験的：Forest Therapy Group
Participants assigned to this arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner.
Sessions will be adapted to participants' functional abilities and special needs and will be conducted in accessible natural environments.
Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
|
Participants assigned to the forest therapy arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner.
Sessions will take place in accessible natural or forest environments and may include guided slow walking, sensory awareness, breathing, relaxation, mindful attention, and reflective activities.
Session content and pace will be adapted to participants' functional abilities and special needs.
Attendance, tolerability, and any adverse events will be documented.
|
|
実験的：Hirudotherapy Group
Participants assigned to this arm will receive six hirudotherapy sessions delivered by a qualified and licensed hirudotherapy practitioner.
Eligibility and contraindications will be assessed before treatment, and participant safety and adverse events will be monitored throughout the intervention period.
Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
|
Participants assigned to the hirudotherapy arm will receive six hirudotherapy sessions delivered by a qualified and licensed practitioner.
Before the intervention, eligibility and contraindications will be assessed.
Medicinal leeches will be applied according to an individualized protocol, taking into account the participant's health condition and safety requirements.
Participants will be monitored for bleeding, local skin reactions, infection, allergic reactions, and other adverse events during and after each session.
|
|
介入なし：Control Group
Participants assigned to this arm will not receive a study-related complementary and alternative health care intervention during the study period.
They will undergo the same baseline and post-intervention assessments as participants in the intervention groups.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Systolic Blood Pressure
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in resting systolic blood pressure from baseline to the post-intervention assessment.
Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure.
A lower post-intervention value compared with baseline will indicate a reduction in systolic blood pressure.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Diastolic Blood Pressure
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in resting diastolic blood pressure from baseline to the post-intervention assessment.
Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure.
A lower post-intervention value compared with baseline will indicate a reduction in diastolic blood pressure.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Psychological Well-Being Assessed With the WHO-5 Well-Being Index
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in psychological well-being from baseline to the post-intervention assessment, measured using the 5-item World Health Organization Well-Being Index (WHO-5).
The raw score ranges from 0 to 25, with higher scores indicating better psychological well-being.
The raw score may also be multiplied by 4 to obtain a percentage score ranging from 0 to 100.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Perceived Stress Assessed With the PSS-10
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in perceived stress from baseline to the post-intervention assessment, measured using the 10-item Perceived Stress Scale (PSS-10).
The total score ranges from 0 to 40, with higher scores indicating greater perceived stress.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Sleep Quality Assessed With the Pittsburgh Sleep Quality Index
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in sleep quality from baseline to the post-intervention assessment, measured using the Pittsburgh Sleep Quality Index (PSQI).
The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Handgrip Strength
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in maximal handgrip strength from baseline to the post-intervention assessment.
Handgrip strength will be measured in kilograms using a hand dynamometer under standardized testing conditions.
Higher values indicate greater grip strength.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Body Fat Percentage
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in body fat percentage from baseline to the post-intervention assessment, measured using a standardized body composition analyzer.
Lower or higher values will be interpreted according to the participant's individual health status.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Body Weight
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in body weight from baseline to the post-intervention assessment.
Body weight will be measured in kilograms using a standardized body composition analyzer, with participants assessed under comparable measurement conditions.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Body Mass Index
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in body mass index from baseline to the post-intervention assessment.
Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m².
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Skeletal Muscle Mass
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in skeletal muscle mass from baseline to the post-intervention assessment.
Skeletal muscle mass will be estimated in kilograms using a standardized bioelectrical impedance body composition analyzer under comparable measurement conditions.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
|
Change in Visceral Fat Level
時間枠：Baseline and after completion of the intervention period, approximately 3 months after baseline
|
Change in visceral fat level from baseline to the post-intervention assessment.
Visceral fat will be estimated using a standardized bioelectrical impedance body composition analyzer and reported according to the device-specific visceral fat rating scale.
Lower scores indicate a lower estimated level of visceral fat.
|
Baseline and after completion of the intervention period, approximately 3 months after baseline
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Laura Zaliene, PhD、Klaipėda University
出版物と役立つリンク
一般刊行物
- Siah CJR, Goh YS, Lee J, Poon SN, Ow Yong JQY, Tam WW. The effects of forest bathing on psychological well-being: A systematic review and meta-analysis. Int J Ment Health Nurs. 2023 Aug;32(4):1038-1054. doi: 10.1111/inm.13131. Epub 2023 Mar 2.
- Qiu Q, Yang L, He M, Gao W, Mar H, Li J, Wang G. The Effects of Forest Therapy on the Blood Pressure and Salivary Cortisol Levels of Urban Residents: A Meta-Analysis. Int J Environ Res Public Health. 2022 Dec 27;20(1):458. doi: 10.3390/ijerph20010458.
- Hosseini M, Jadidi A, Derakhshan Barjoei MM, Salehi M. Applications of leech therapy in medicine: a systematic review. Front Med (Lausanne). 2024 Sep 16;11:1417041. doi: 10.3389/fmed.2024.1417041. eCollection 2024.
- Lauche R, Cramer H, Langhorst J, Dobos G. A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee. Clin J Pain. 2014 Jan;30(1):63-72. doi: 10.1097/AJP.0b013e31828440ce.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- CAM-SN-HFT-2026-01
- SAM-003-K-0002 (その他の助成金/資金番号：Ministry of Health of the Republic of Lithuania)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。